Herpes Simplex Virus Infections

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 1382-1387

  Ito, James I ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Drug of choice for treatment of HSV mucocutaneous infection in HCT recipient acyclovir; Epidemiology of HSV infection in HCT recipient; Herpes simplex virus infections; HSV immunology in HCT recipient; Prophylaxis; Prophylaxis and treatment guidelines for herpes simplex virus (HSV)

Indexed keywords

EID: 78649917360     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch91     Document Type: Chapter

References (53)

1. Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplantation. J Infect Dis 1980; 142: 338-46.
2. Meyers JD. Infections in marrow recipients. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and Practice of Infectious Diseases, 2nd edn. New York: John Wiley & Sons; 1984. pp. 1674-6.
3. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes simplex virus infections: a randomized, doubleblind controlled trial in bone marrow transplant recipients. N Engl J Med 1981; 305: 63-7.
4. Gluckman E, Lotsberg J, Devergie A et al. Prophylaxis of herpes infections after bone marrow transplantation by oral acyclovir. Lancet 1983; 2: 706-8.
5. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex reactivation after marrow transplantation. Ann Intern Med 1984; 100: 823-8.
6. Roizman B, Knipe DM, Whitley RJ. Herpes simplex viruses. In: Knipe DM, Howley PM, editors. Fields Virology, 5th edn. Philadelphia: Lippincott, Williams & Wilkins; 2007. pp. 2501-601.
7. Deschamps M, Mercier-Lethondal P, Certoux JM et al. Deletions within the HSV-tk transgene in long-lasting circulating gene-modifi ed T-cells infused with a hematopoietic graft. Blood 2007; 110: 3842-52.
8. Ciceri F, Bonini C, Marktel S et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007; 109: 4698-707.
9. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specifi c immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modifi ed donor T-cells after allogeneic hematopoietic cell transplantation. Blood 2006; 107: 2294-302.
10. Stanberry LR, Kern ER, Richards JT et al. Genital herpes in guinea pigs: pathogenesis of primary infection and description of recurrent disease. J Infect Dis 1983; 146: 397-404.
11. Bastian FO, Rabson AS, Yee CL, Tralka TS. Herpesvirus hominis: isolation from human trigeminal ganglion. Science 1972; 178: 306-7.
12. + T cells maintain HSV-1 latency. Immunol Res 2006; 36: 119-26.
13. Sheridan BS, Knickellbein JE, Hendricks RL. CD8 T cells and latent herpes simplex virus type 1: keeping the peace in sensory ganglia. Expert Opin Biol Ther 2007; 7: 1323-31.
14. Kapoor AK, Nash AA, Wildy P et al. Pathogenesis of herpes simplex virus in congenitally athymic mice: the relative roles of cell-mediated and humoral immunity. J General Virol 1982; 60: 225-33.
15. Balachandran N, Bacchetti S, Rawls WE. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to fi ve glycoproteins of herpes simplex virus type-2. Infect Immun 1982; 37: 1132-7.
16. Eisenberg R, Cerini CP, Heilman CJ et al. Synthetic glycoprotein d-related peptides protect mice against herpes simplex virus challenge. J Virol 1985; 55: 1014-17.
17. Manickan E, Rouse BT. Role of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-defi cient mouse models. J Virol 1995; 69: 8178-9.
18. + T lymphocytes. Cell 1994; 77: 525-35.
19. Koelle DM, Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Ann Rev Med 2008; 59: 381-95.
20. Storek J, Witherspoon RP. Immunologic reconstitution after hematopoietic stem cell transplantation. In: Atkinson K, editor. Clinical Bone Marrow and Blood Stem Cell Transplantation. Cambridge, UK: Cambridge University Press; 2000. pp. 111-46.
21. Wade JC, Day LM, Crowley JJ, Meyers JD. Recurrent infection with herpes simplex virus after marrow transplantation. Role of the specifi c immune response and acyclovir treatment. J Infect Dis 1984; 149: 750-6.
22. Nahmias AJ, Lee FK, Bechman-Nahmias S. Seroepidemiological and sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis 1990; 69: 19-36.
23. Xu F, Sternberg MR, Kottiri BJ et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296: 964-73.
24. Rawls WE, Iwamoto K, Adam E, Melnick JL. Measurement of antibodies to herpesvirus type 1 and 2 in human sera. J Immunol 1970; 104: 599-606.
25. Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis 1994; 18: 273-84.
26. Kingreen D, Nitsche A, Beyer J, Siegert W. Herpes simplex infection of the jejunum occurring in the early post-transplantation period. Bone Marrow Transplant 1997; 20: 989-91.
27. Naik HR, Chandrasekar PH. Herpes simplex virus (HSV) colitis in a bone marrow transplant recipient. Bone Marrow Transplant 1996; 17: 285-6.
28. Ramsey PG, Fife KH, Hackman RC, Meyers JD, Corey L. Herpes simplex virus pneumonia. Ann Intern Med 1982; 97: 813-20.
29. Ljungman P, Ellis MN, Hackman RC, Shepp DH, Meyers JD. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis 1990; 162: 244-8.
30. Johnson JR, Egaas S, Gleaves CA, Hackman R, Bowden RA. Hepatitis due to herpes simplex virus in marrow-transplant recipients. Clin Infect Dis 1992; 14: 38-45.
31. Gruson D, Hilbert G, Le Bail B, Portel L, Boiron JM, Reiffers J, Gbikpi-Benissan G. Fulminant hepatitis due to herpes simplex virus-type 2 in early phase of bone marrow transplantation. Hematol Cell Ther 1998; 40: 41-4.
32. Whitley RJ. Herpes simplex encephalitis: adolescents and adults. Antiviral Res 2006; 71: 141-8.
33. Strick LB, Wald A. Diagnostics for herpes simplex virus: is PCR the new gold standard?. Mol Diagn Ther 2006; 10: 17-28.
34. Lakerman FD, Whitley RJ, the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction 50 cerebrospinal fl uid from brain biopsied patients and correlation with disease. J Infect Dis 1995; 171: 857-63.
35. Lundgren G, Wilczek H, Lonnqvist B, Lindholm A, Wahren B, Ringden O. Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis 1985; 47(Suppl): 137-44.
36. Wade JC, Newton B, McLaren C, Flournoy N, Keeney RE, Meyers JD. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med 1982; 96: 265-9.
37. Shepp DH, Newton BA, Dandliker PS, Flournoy N, Meyers JO. Oral acyclovir mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients. Ann Intern Med 1985; 102: 783-5.
38. Bryant P, Sasadeusz J, Carapetis J, Waters K, Curtis N. Successful treatment of foscarnetresistant herpes simplex stomatitis with intravenous cidofovir in a child. Pediatr Infect Dis J 2001; 20: 1083-6.
39. Blot N, Schneider P, Young P, Janvresse C, Dehesdin D, Tron P, Vannier JP. Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone Marrow Transplant 2000; 26: 903-5.
40. Darville JM, Ley BE, Roome AP, Foot AB. Acyclovir-resistant herpes simplex virus infections in a bone marrow transplant population. Bone Marrow Transplant 1998; 22: 587-9.
41. Wyles DL, Patel A, Madinger N, Bessesen M, Krause PR, Weinberg A. Development of herpes simplex virus disease in patients who are receiving cidofovir. Clin Infect Dis 2005; 41: 676-80.
42. Center for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of the CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR 2000; 49 (RR-10): 15-16.
43. Shepp DH, Dandliker PS, Fournoy N, Meyers JD. Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients. Transplantation 1987; 43: 654-8.
44. Ljungman P, Wilczek H, Gahrton G et al. Longterm acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpesvirus antigens in vitro. Bone Marrow Transplant 1986; 1: 185-92.
45. Wade JC, McLaren C, Meyers JD. Frequency and signifi cance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis 1983; 48: 1077-82.
46. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007; 196: 266-70.
47. Boeckh M, Kim HW, Flowers MED, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation-a randomized double-blind placebo-controlled study. Blood 2006; 107: 1800-5.
48. Meyers JD, Reed EC, Shepp DH et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318: 70-5.
49. Ljungman P, de la Camara R, Milpied N et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Transplantation 2002; 99: 3050-6.
50. Perren TJ, Powles RL, Easton D, Stolle K, Selby PS. Prevention of herpes zoster in patients by longer-term oral acyclovir after allogeneic bone marrow transplantation. Am J Medical 1988; 85(Suppl. 2A): 99-101.
51. Lundgren G, Wilczek H, Lonnqvist B, Lindholm A, Wahren B, Ringden O. Acyclovir prophylaxis in bone marrow transplant recipients. Scan J Infect Dis Suppl 1985; 47: 137-44.
52. Winston DJ, Young JA, Pullarkat V et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem-cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. Epub 2008 February 19, PMID 2006228.
53. Koelle DM. Vaccines for herpes simplex virus infections. Curr Opin Investig Drugs 2006; 7: 136-41.